EVEREST MED-B: 2024 Interim Report
Hong Kong stocks soared in the afternoon. Genting New Vision-B (01952) rose more than 5%, while E Jiahe's sales of Nai Fuke soared significantly, with product sales in the first half of the year increasing by more than 1.5 times compared to the previous p
Yunding Xinyao-B (01952) rose more than 5% in the afternoon, as of the time of writing, up 5.80%, at HKD 21.9, with a turnover of HKD 67.6309 million.
Analysts Have Made A Financial Statement On Everest Medicines Limited's (HKG:1952) Half-Yearly Report
[Brokerage Focus] Bocom Intl raises target price by 7.32% for Genting New York (01952) as YiJiaHe and NaiFuKang sales volume significantly exceeds expectations.
Kingwu Financial News | Bocom Intl released its research report, indicating that the sales performance of Cloud Glory New Shine (01952) in 1H24 was excellent: product sales increased by 158% to 0.302 billion yuan compared to the previous period, exceeding market expectations. This includes: 1) After Nafucan was commercialized in mainland China in May, sales reached 0.167 billion yuan in a month and a half. The NMPA has accepted the supplementary application for full product approval, expected to be approved in 1H25. Future sales growth will mainly come from the promotion and education of guidelines, and possible negotiations for medical insurance access; 2) Yijia sales amounted to 0.134 billion yuan (a 35% increase from 2H23), with subsequent growth prospects being the main focus.
Genting Xinyao-B (01952): The value of scale commercialization is validated again, and the dual-wheel drive continues to boost the value curve.
On August 27th, the mid-year financial results (2024) of Genting Xin Yao-B (01952) were just released. According to the financial report, the company's current revenue reached 0.302 billion yuan (RMB, the same unit), a significant year-on-year increase of 3289.74%.
Genting New Star (01952) widened its interim loss to 0.632 billion RMB and did not pay dividends.
Jingu Financial News | Genting Xinyao (01952) announced that for the six months ended June 30, 2024, the company's equity holders recorded a loss attributable to the period of 6.32 billion yuan (RMB, the same below), a year-on-year increase of 49.29%. This is mainly due to the one-time, non-recurring impairment loss of intangible assets related to the mRNACOVID-19 vaccine. The basic loss per share was 1.97 yuan, and no dividend was declared. During the period, revenue was recorded at 3.02 billion yuan, a year-on-year increase of 3289.74%, mainly due to the continuous expansion of sales by Yijia in mainland China and Hong Kong, and the listing of Naifukang in mainland China and Singapore.
Express News | Everest Medicines Announces Interim Results for First Half of 2024
Press Release: Everest Medicines Announces Interim Results for First Half of 2024
Analysts Expect Breakeven For Everest Medicines Limited (HKG:1952) Before Long
Genting New Star-B (01952.HK) announced its interim performance: revenue surged to 0.3015 billion yuan, with a significant increase in gross margin.
Great Wall News August 28th: Genting XinYao-B (01952.HK) announced its interim results. For the six months ended June 30, 2023, driven by Yijia and Nai Fu Kang, the Group recorded revenue of RMB 301.5 million, compared to RMB 8.9 million for the six months ended June 30, 2023. The gross profit for the period reached RMB 2.31 billion, compared to RMB 557.7 million for the same period of the previous year. The gross margin increased from 62.7% for the six months ended June 30, 2023 to 76.6% for the six months ended June 30, 2024, and the gross margin (excluding
Express News | Everest Medicines H1 Net Income RMB -632.4 Million
Express News | Everest Medicines H1 Operating Income RMB -671.8 Million
Express News | Everest Medicines H1 Revenue RMB 301.5 Million
EVEREST MED-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
Hong Kong stocks abnormal | Galaxy New Glory-B (01952) rose more than 5% in late trading, and the self-developed new mRNA personalized tumor treatment vaccine officially launched clinical trials.
Yunding Xinyao-B (01952) rose more than 5% at the close. As of the time of publication, it rose by 4.54%, to 19.34 Hong Kong dollars, with a transaction amount of 39.5861 million Hong Kong dollars.
Express News | Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (Iit) for Personalized Mrna Cancer Vaccine Program Evm16
Upgrading, integration, transformation | The strategic transformation of Cloudtop New Glory-B (01952) from the all-staff meeting.
The theme of this meeting is "upgrade, integration, and transformation." It reviewed the transformation and reform of Genting Xin Yao since 2022, emphasized the strategic focus on the "blue ocean" field, improving operational efficiency and establishing the best commercial practice, building an entrepreneurial culture, and moving towards the goal of achieving the 2030 vision.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Everest Medicines to Announce 2024 Interim Results on August 28, 2024
SHANGHAI, Aug. 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and
The board of directors of Genting New York-B (01952.HK) will hold a meeting on August 27th to consider and approve mid-term performance.
Gelonghui August 5th | Genting New York-B (01952.HK) announced that the board of directors meeting is scheduled to be held on Tuesday, August 27, 2024, to consider and approve the interim performance of the group for the six months ended June 30, 2024, and to deal with other matters.
No Data
No Data